Focus: Shield Therapeutics is a biotech company focused on small-molecule oncology and iron-deficiency treatments, with a marketed product (ACCRUFER) at peak lifecycle and generic/ANDA products in post-LOE phase.
Profile data last refreshed 42m ago · AI intelligence enriched 1w ago
Small, commercially viable but operationally opaque; best for specialized roles (legal, compliance) rather than R&D or commercial expansion.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Approved NDA with pediatric and adult formulations; core revenue generator with 12+ year patent protection.
Help build intelligence for Shield Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Shield Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
ANDA generic post-LOE; likely margin-based revenue stream in competitive prostate cancer market.
ANDA generic post-LOE in mature ophthalmic antihistamine segment; limited growth potential.
1 discontinued, 0 duplicate formulations not shown
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo